Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110
, Reference
- Alvarado-Miranda, A.; Lara-Medina, F.U.; Muñoz-Montaño, W.R.; Zinser-Sierra, J.W.; Galeana, P.A.C.; Garza, C.V.; Sanchez Benitez, D.; Limón Rodríguez, J.A.; Arce Salinas, C.H.; Guijosa, A.; et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. [Google Scholar] [CrossRef] [PubMed]
| Total (Events) | Median (95% CI) | p-Value | HR (95% CI) | p-Value | |
|---|---|---|---|---|---|
| ECOG PS | 0.972 | ||||
| 0–1 | 136 (62) | 42.9 (31.1–54.7) | |||
| ≥2 | 27 (15) | 63.4 (33.9–92.8) | |||
| Hormonal status | 0.199 | ||||
| Pre- or peri-menopausal | 54 (19) | 46.5 (27.2–65.8) | |||
| Postmenopausal | 109 (58) | 52.3 (34.5–70.2) | |||
| Tumor status | 0.547 | ||||
| ≤T2 | 62 (25) | 62.4 (48.5–76.3) | |||
| T3 | 40 (21) | 40.9 (30.7–51.1) | |||
| T4 | 61 (31) | 41.8 (25.6–58.1) | |||
| Nodal status | 0.707 | ||||
| N0 | 24 (9) | 65.6 (29.7–101.4) | |||
| N1 | 59 (27) | 44.9 (36.7–53.2) | |||
| N2 | 51 (25) | 42.3 (33.4–51.1) | |||
| N3 | 29 (16) | 52.8 (25.7–79.9) | |||
| Disease state | 0.947 | ||||
| Recurrent disease | 131 (61) | 46.5 (33.1–60.0) | |||
| Metastatic disease | 32 (16) | 47.9 (16.2–79.7) | |||
| Histological subtype | 0.884 | ||||
| IDC | 135 (63) | 52.8 (35.5–70.1) | |||
| ILC | 28 (14) | 37.4 (26.4–48.3) | |||
| Ki67 | 0.507 | ||||
| <20 | 46 (17) | 62.39 (27.7–97.1) | |||
| ≥20 | 50 (24) | 46.5 (21.7–71.4) | |||
| Unknown | 67 (36) | 52.3 (32.2–72.5) | |||
| SBR | 0.085 | ||||
| Low | 13 (5) | 80.1 (31.7–128.6) | |||
| Intermediate and high | 130 (66) | 40.0 (34.3–47.5) | |||
| Unknown | 20 (6) | 63.4 (42.4–84.4) | |||
| ER | 0.451 | ||||
| Negative | 7 (4) | 18.1 (17.8–18.5) | |||
| Positive | 156 (73) | 47.9 (40.1–64.5) | |||
| PgR | 0.447 | ||||
| Negative | 32 (17) | 34.3 (11.5–57.3) | |||
| Positive | 131 (60) | 47.9 (28.1–67.8) | |||
| ER/PgR | 0.533 | ||||
| ER+, PgR+ | 124 (56) | 52.3 (32.6–72.1) | |||
| ER+, PgR− | 32 (17) | 34.4 (11.5–57.3) | |||
| ER−, PgR+ | 7 (4) | 18.1 (17.8–18.5) | |||
| Type of surgery | 0.387 | ||||
| BCS | 17 (5) | 98.9 (8.5–189.4) | |||
| MRM | 121 (61) | 44.9 (34.7–55.2) | |||
| None | 25 (11) | 36.3 (0–79.57) | |||
| Adjuvant endocrine Therapy | 0.748 | ||||
| Tamoxifen | 57 (26) | 52.3 (29.6–75.1) | |||
| Aromatase inhibitors | 106 (51) | 42.8 (26.9–58.8) | |||
| Disease-free interval % (n/N) | 0.993 | ||||
| Newly metastatic disease | 32 (16) | 47.9 (16.6–79.7) | |||
| ≤24 months | 40 (18) | 46.5 (24.3–68.7) | |||
| >24 months | 91 (43) | 44.9 (30.2–59.7) | |||
| Number of metastases % (n/N) | 0.010 | 1.129 (0.879–1.449) | 0.341 | ||
| 1 place | 105 (47) | 53.5 (34.9–72.1) | |||
| 2 places | 36 (22) | 34.4 (30.0–47.8) | |||
| ≥3 places | 12 (6) | 26.4 (9.5–43.3) | |||
| CNS involvement * | 10 (2) | X | |||
| Disease site % (n/N) | 0.068 | ||||
| Visceral | 84 (40) | 40.4 (21.4–59.4) | |||
| Non-visceral | 16 (3) | X | |||
| Bone | 63 (34) | 44.4 (37.3–52.6) | |||
| Treatment | 0.122 | 1.262 (0.947–1.683) | 0.112 | ||
| XELIA | 95 (45) | 53.5 (30.3–76.6) | |||
| Hormone therapy | 35 (15) | 47.9 (24.6–71.2) | |||
| Chemotherapy | 33 (17) | 40.4 (34.7–61.3) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alvarado-Miranda, A.; Lara-Medina, F.U.; Muñoz-Montaño, W.R.; Zinser-Sierra, J.W.; Galeana, P.A.C.; Garza, C.V.; Sanchez Benitez, D.; Limón Rodríguez, J.A.; Arce Salinas, C.H.; Guijosa, A.; et al. Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. Curr. Oncol. 2024, 31, 7177-7179. https://doi.org/10.3390/curroncol31110529
Alvarado-Miranda A, Lara-Medina FU, Muñoz-Montaño WR, Zinser-Sierra JW, Galeana PAC, Garza CV, Sanchez Benitez D, Limón Rodríguez JA, Arce Salinas CH, Guijosa A, et al. Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. Current Oncology. 2024; 31(11):7177-7179. https://doi.org/10.3390/curroncol31110529
Chicago/Turabian StyleAlvarado-Miranda, Alberto, Fernando Ulises Lara-Medina, Wendy R. Muñoz-Montaño, Juan W. Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal Garza, Daniel Sanchez Benitez, Jesús Alberto Limón Rodríguez, Claudia Haydee Arce Salinas, Alberto Guijosa, and et al. 2024. "Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110" Current Oncology 31, no. 11: 7177-7179. https://doi.org/10.3390/curroncol31110529
APA StyleAlvarado-Miranda, A., Lara-Medina, F. U., Muñoz-Montaño, W. R., Zinser-Sierra, J. W., Galeana, P. A. C., Garza, C. V., Sanchez Benitez, D., Limón Rodríguez, J. A., Arce Salinas, C. H., Guijosa, A., & Arrieta, O. (2024). Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. Current Oncology, 31(11), 7177-7179. https://doi.org/10.3390/curroncol31110529
